AAFPRS President Addresses Concerns About Moderna COVID-19 Vaccine
AAFPRS will continue monitoring reports of incidents of reactions in patients with dermal fillers who received the Moderna COVID-19 vaccine.
AAFPRS will continue monitoring reports of incidents of reactions in patients with dermal fillers who received the Moderna COVID-19 vaccine.
The company is building a dedicated sales and medical affairs team to drive adoption of its neurotoxin and provide practices with direct clinical and commercial support.